文献速递腹部MR

钆塞酸增强MRI识别与预测巨梁状-团块型肝细胞癌

Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging.
PubMed 文献 · Eur Radiol · 2021-04-15

多因素分析显示高血小板计数、低肿瘤/肝脏ADC比值及坏死或严重缺血为MTM-HCC独立预测因素,联合模型平均AUC为0.81,敏感度57%、特异度92%。

要点

  • 坏死或严重缺血是MTM-HCC的敏感影像征象,单独识别86%的MTM-HCC,特异度66%。
  • 联合高血小板计数(≥163.5×10^3/ul)、低肿瘤/肝脏ADC比值(≤1.05)及坏死或严重缺血可提高预测特异度至92%。
  • 日常阅片遇HCC伴坏死或严重缺血时,应提示MTM-HCC可能并建议结合实验室指标综合评估。

关键影像表现/征象

  • 坏死或严重缺血是MTM-HCC的敏感影像征象,单独即可识别86%的MTM-HCC,特异度66%。
  • 低肿瘤/肝脏ADC比值(≤1.05)为MTM-HCC的独立预测因素(OR=3.05,95%CI 1.23-7.55,p=0.016)。
  • 高血小板计数(≥163.5×10^3/ul)为MTM-HCC的独立预测因素(OR=3.20,95%CI 1.29-7.96,p=0.012)。
  • 坏死或严重缺血为MTM-HCC的独立预测因素(OR=11.61,95%CI 3.99-33.76,p<0.001)。

诊断标准与关键数值

  • 坏死或严重缺血单独识别MTM-HCC的敏感度86%、特异度66%。
  • 基于回归的诊断模型平均AUC为0.81(95%CI 0.71-0.90),敏感度57%、特异度92%。
  • 高血小板计数截断值为≥163.5×10^3/ul,低肿瘤/肝脏ADC比值截断值为≤1.05。

临床应用与阅片要点

  • 阅片时注意HCC内坏死或严重缺血征象,结合血小板计数及ADC比值可无创提示MTM-HCC亚型。
  • 联合模型特异度高达92%,可用于筛选需进一步病理确认或强化治疗策略的患者。

局限性

  • 诊断模型敏感度仅57%,可能漏诊部分MTM-HCC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To identify image features of macrotrabecular-massive (MTM) hepatocellular carcinoma (HCC) and to determine its role in predicting MTM-HCC.

METHODS: Patients who underwent preoperative gadoxetic acid-enhanced MRI and with surgery proven HCC were retrospectively included. Imaging features were assessed according to Liver Imaging Reporting and Data System. Quantitative measurements were recorded. Clinical characteristics and imaging findings were compared between MTM-HCCs and non-MTM-HCCs. Predictive factors of MTM-HCC were screened with univariate analyses and then identified with multivariate logistic regression. A regression-based diagnostic model was constructed. ROC analyses were used to determine cutoff values, AUC, and corresponding 95% confidence interval (CI) of findings. The diagnostic performance was validated by 10-fold cross-validation.

RESULTS: One hundred and forty-one patients with 37 MTM-HCCs were included. Multivariate analyses identified high platelet count (≥ 163.5 × 103/ul, odds ratio = 3.20; 95% CI: 1.29, 7.96; p = 0.012), low tumor-to-liver ADC ratio (≤ 1.05, odds ratio = 3.05; 95% CI, 1.23 - 7.55; p = 0.016), and necrosis or severe ischemia (odds ratio = 11.61; 95% CI, 3.99 - 33.76, p < 0.001) as independent predictors of MTM-HCC. Necrosis or severe ischemia alone helped identify 86% MTM-HCCs with a specificity of 66%. The average AUCs were 0.81 (95% CI: 0.71, 0.90) for the regression-based diagnostic model, with a sensitivity of 57% and specificity of 92%.

CONCLUSIONS: Necrosis or severe ischemia was a sensitive imaging feature of MTM-HCC. Noninvasive prediction of this subtype can be achieved with good accuracy and excellent specificity when findings were combined.

KEY POINTS: • The macrotrabecular-massive (MTM) hepatocellular carcinoma (HCC) represents an aggressive subtype of HCC and is associated with poor prognosis. • Imaging features of necrosis or severe ischemia alone helped identify 86% MTM-HCCs with a specificity of 66%. • A regression-based diagnostic model including high platelet count (≥ 163.5 × 103/ul), low tumor-to-liver ADC ratio (≤ 1.05), and necrosis or severe ischemia can provide noninvasive assessment of MTM-HCC with good accuracy and high specificity.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen J, Xia C, Duan T, et al. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol. 2021. PMID: 33856520. doi:10.1007/s00330-021-07898-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。